These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22185670)

  • 1. Oxadiazoles in medicinal chemistry.
    Boström J; Hogner A; Llinàs A; Wellner E; Plowright AT
    J Med Chem; 2012 Mar; 55(5):1817-30. PubMed ID: 22185670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted oxadiazoles: a patent review (2010 - 2012).
    Zarghi A; Hajimahdi Z
    Expert Opin Ther Pat; 2013 Sep; 23(9):1209-32. PubMed ID: 23663160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of oxadiazole-based FLAP inhibitors.
    Bartolozzi A; Abeywardane A; Bosanac T; Broadwater JA; Chen Z; Hutzler JM; Huber JD; Nemoto P; Olague A; Riether D; Simpson T; Takahashi H; Wu L; Zhang Y; Zindell RM
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4652-4659. PubMed ID: 28927794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
    DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
    Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Support vector machines classification of hERG liabilities based on atom types.
    Jia L; Sun H
    Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,3,4-Oxadiazole Containing Compounds As Therapeutic Targets For Cancer Therapy.
    Ahsan MJ
    Mini Rev Med Chem; 2022; 22(1):164-197. PubMed ID: 33634756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxadiazole scaffolds in anti-tuberculosis drug discovery.
    De SS; Khambete MP; Degani MS
    Bioorg Med Chem Lett; 2019 Aug; 29(16):1999-2007. PubMed ID: 31296357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and one-pot and microwave-assisted synthesis of 2-amino/5-aryl-1,3,4-oxadiazoles bearing a benzimidazole moiety as antioxidants.
    Kerimov İ; Ayhan-Kilcigil G; Özdamar ED; Can-Eke B; Çoban T; Özbey S; Kazak C
    Arch Pharm (Weinheim); 2012 Jul; 345(7):549-56. PubMed ID: 22467524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of phosphodiesterase (PDE) inhibitors on human ether-a-go-go related gene (hERG) channel activity.
    Yunomae K; Ichisaki S; Matsuo J; Nagayama S; Fukuzaki K; Nagata R; Kito G
    J Appl Toxicol; 2007; 27(1):78-85. PubMed ID: 17146843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).
    Warmus JS; Flamme C; Zhang LY; Barrett S; Bridges A; Chen H; Gowan R; Kaufman M; Sebolt-Leopold J; Leopold W; Merriman R; Ohren J; Pavlovsky A; Przybranowski S; Tecle H; Valik H; Whitehead C; Zhang E
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6171-4. PubMed ID: 18951019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxazolidinones as novel human CCR8 antagonists.
    Jin J; Wang Y; Wang F; Kerns JK; Vinader VM; Hancock AP; Lindon MJ; Stevenson GI; Morrow DM; Rao P; Nguyen C; Barrett VJ; Browning C; Hartmann G; Andrew DP; Sarau HM; Foley JJ; Jurewicz AJ; Fornwald JA; Harker AJ; Moore ML; Rivero RA; Belmonte KE; Connor HE
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1722-5. PubMed ID: 17267215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters.
    Gleeson P; Bravi G; Modi S; Lowe D
    Bioorg Med Chem; 2009 Aug; 17(16):5906-19. PubMed ID: 19632124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel tricyclic benzoxazines as potent 5-HT(1A/B/D) receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045).
    Bromidge SM; Arban R; Bertani B; Bison S; Borriello M; Cavanni P; Dal Forno G; Di-Fabio R; Donati D; Fontana S; Gianotti M; Gordon LJ; Granci E; Leslie CP; Moccia L; Pasquarello A; Sartori I; Sava A; Watson JM; Worby A; Zonzini L; Zucchelli V
    J Med Chem; 2010 Aug; 53(15):5827-43. PubMed ID: 20590088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Part II: Design, synthesis and antitumor action of C3/C3 bisfluoroquinolones linked-cross 2, 5-[1, 3, 4]oxadiazole.
    Hu GQ; Yang Y; Yi L; Wang X; Zhang ZQ; Xie SQ; Huang WL
    Yao Xue Xue Bao; 2010 Aug; 45(8):1012-6. PubMed ID: 21348428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
    van der Stelt M; Cals J; Broeders-Josten S; Cottney J; van der Doelen AA; Hermkens M; de Kimpe V; King A; Klomp J; Oosterom J; Pols-de Rooij I; de Roos J; van Tilborg M; Boyce S; Baker J
    J Med Chem; 2011 Oct; 54(20):7350-62. PubMed ID: 21923175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.
    Olesen PH; Sørensen AR; Ursø B; Kurtzhals P; Bowler AN; Ehrbar U; Hansen BF
    J Med Chem; 2003 Jul; 46(15):3333-41. PubMed ID: 12852764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
    Butini S; Brindisi M; Gemma S; Minetti P; Cabri W; Gallo G; Vincenti S; Talamonti E; Borsini F; Caprioli A; Stasi MA; Di Serio S; Ros S; Borrelli G; Maramai S; Fezza F; Campiani G; Maccarrone M
    J Med Chem; 2012 Aug; 55(15):6898-915. PubMed ID: 22779702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zwitterionic CRTh2 antagonists.
    Luker T; Bonnert R; Paine SW; Schmidt J; Sargent C; Cook AR; Cook A; Gardiner P; Hill S; Weyman-Jones C; Patel A; Thom S; Thorne P
    J Med Chem; 2011 Mar; 54(6):1779-88. PubMed ID: 21355602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.